doi: 10.1056/NEJM200505123521923.
Antibody response to aerosolized transgenic human alpha1-antitrypsin
- PMID:15888711
- DOI: 10.1056/NEJM200505123521923
Item in Clipboard
Antibody response to aerosolized transgenic human alpha1-antitrypsin
L Terry Spencer et al. N Engl J Med..
Display options
Format
Display options
Format
No abstract available
Similar articles
- Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice.Song S, Witek RP, Lu Y, Choi YK, Zheng D, Jorgensen M, Li C, Flotte TR, Petersen BE.Song S, et al.Hepatology. 2004 Oct;40(4):918-24. doi: 10.1002/hep.20404.Hepatology. 2004.PMID:15382177
- Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics.Tebbutt SJ.Tebbutt SJ.Curr Opin Mol Ther. 2000 Apr;2(2):199-204.Curr Opin Mol Ther. 2000.PMID:11249642Review.
- Expression of human alpha 1 antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer.Saylors RL 3rd, Wall DA.Saylors RL 3rd, et al.Mol Genet Metab. 1998 Mar;63(3):198-204. doi: 10.1006/mgme.1997.2665.Mol Genet Metab. 1998.PMID:9608542
- Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency.Chiuchiolo MJ, Kaminsky SM, Sondhi D, Mancenido D, Hollmann C, Crystal RG.Chiuchiolo MJ, et al.Hum Gene Ther Clin Dev. 2014 Sep;25(3):112-33. doi: 10.1089/humc.2014.2513.Hum Gene Ther Clin Dev. 2014.PMID:25238276Clinical Trial.No abstract available.
- Gene therapy progress and prospects: alpha-1 antitrypsin.Stecenko AA, Brigham KL.Stecenko AA, et al.Gene Ther. 2003 Jan;10(2):95-9. doi: 10.1038/sj.gt.3301947.Gene Ther. 2003.PMID:12571637Review.
Cited by
- Directions and applications of CRISPR technology in livestock research.Lamas-Toranzo I, Ramos-Ibeas P, Pericuesta E, Bermejo-Álvarez P.Lamas-Toranzo I, et al.Anim Reprod. 2018 Aug 17;15(3):292-300. doi: 10.21451/1984-3143-AR2018-0075.Anim Reprod. 2018.PMID:34178152Free PMC article.
- Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.Petrache I, Hajjar J, Campos M.Petrache I, et al.Biologics. 2009;3:193-204. doi: 10.2147/btt.2009.3088. Epub 2009 Jul 13.Biologics. 2009.PMID:19707408Free PMC article.
- Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam DH, Teckman J, Nelson DR, McCaleb ML, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A.Wanner A, et al.Chronic Obstr Pulm Dis. 2015 Apr 28;2(2):177-190. doi: 10.15326/jcopdf.2.2.2015.0132.Chronic Obstr Pulm Dis. 2015.PMID:28848840Free PMC article.
- Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.Mosheimer B, Alzner R, Wiedermann CJ.Mosheimer B, et al.Arch Immunol Ther Exp (Warsz). 2007 Nov-Dec;55(6):399-403. doi: 10.1007/s00005-007-0045-3. Epub 2007 Dec 3.Arch Immunol Ther Exp (Warsz). 2007.PMID:18060368Free PMC article.
- Expression of modified gene encoding functional human alpha-1-antitrypsin protein in transgenic tomato plants.Agarwal S, Singh R, Sanyal I, Amla DV.Agarwal S, et al.Transgenic Res. 2008 Oct;17(5):881-96. doi: 10.1007/s11248-008-9173-8. Epub 2008 Mar 5.Transgenic Res. 2008.PMID:18320339
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical